Abdulilah Mayet | Neuropharmacology | Excellence in Research

Published on 12/06/202512/06/2025 by Top Pharmaceutical

Abdulilah Mayet | Neuropharmacology | Excellence in Research

Assoc. Prof. Dr. Abdulilah Mayet, King Khalid University, Saudi Arabia

Assoc. Prof. Dr. Abdulilah Mohammad Mayet is an accomplished expert in Electrical Engineering, currently serving at King Khalid University 🇸🇦. With a Ph.D. from KAUST 🎓, he has pioneered research in MEMS/NEMS, nanofabrication, and AI-integrated sensor systems 🤖. A prolific inventor with 8️⃣ patents and 28+ publications 📚, Dr. Mayet has collaborated with global institutions including UC Irvine 🇺🇸 and Cornell University. His leadership spans academia, industry, and innovation 🚀, notably as CEO of Qimam Abha Company and a Fulbright Scholar. Fluent in Arabic and English 🗣️, he inspires innovation across engineering and technology frontiers 🌍.

Publication Profile

Orcid

Education

Assoc. Prof. Dr. Abdulilah Mayet holds a distinguished academic background in Electrical and Electronics Engineering ⚡. He earned his Ph.D. in Electrical Engineering from King Abdullah University of Science and Technology (KAUST) in April 2016 📅, following his M.Sc. in Electrical Engineering from the same institution in June 2011 🧠. His academic journey began with a B.Sc. in Electrical and Electronics Engineering from King Fahd University of Petroleum and Minerals (KFUPM), Dhahran, Saudi Arabia in June 1991 🏫. This strong educational foundation has powered his cutting-edge contributions to nanotechnology, MEMS/NEMS, and semiconductor innovation 🔬🚀.

Experience

Assoc. Prof. Dr. Abdulilah Mayet brings over 25 years of pioneering experience in nanotechnology, MEMS/NEMS, and VLSI design 💡. Currently, he serves as a Supervisor of the VLSI Design Group and a Visiting Professor at UC Irvine, while also being a Fulbright Scholar Fellow 🇺🇸. As an Associate Professor at King Khalid University, he leads initiatives in nanofabrication, AI-driven FPGA teaching, and research commercialization 🧪. Formerly CTO at SEMC, he managed a 4,000m² fab facility. His career spans innovations in NEM switches, amorphous metals, and MEMS platforms, with leadership roles at the Misk 2030 Leaders Program and Saudi Leadership Society 🌍🔬.

Awards

Assoc. Prof. Dr. Abdulilah Mayet has made remarkable contributions to science and engineering, notably by independently conceptualizing and demonstrating the first-ever fully amorphous metal fabricated in a CMOS fab 🧪🔬. He has published 28 journal papers (24 as first/corresponding author) and 7 conference papers 📝. His research has attracted over SAR 26 million in grants, supporting startups and lab establishments 💰. With 8 intellectual properties registered, he continues pushing innovation 🚀. Dr. Mayet has taught a wide range of advanced courses and mentored MSc students 🎓, while actively shaping curriculum development at both undergraduate and graduate levels 📖👨‍🏫.

Research Focus

Assoc. Prof. Dr. Abdulilah Mayet focuses on cutting-edge research in intelligent measurement systems, non-destructive testing (NDT), and sensor-based technologies within the realm of electrical and electronic engineering ⚡. His work integrates artificial intelligence 🤖, machine learning, and ANNs for enhanced precision in multiphase flow analysis, pipeline diagnostics, and material characterization. He also explores nanoelectronics, MEMS/NEMS, and gamma-ray-based detection systems for industrial and biomedical applications 🧠🏭. His multidisciplinary approach bridges engineering with sustainability, fluid mechanics, and healthcare innovation, making his contributions vital to the energy, oil & gas, and emerging technologies sectors 🌍💡.

Publication Top Notes

Multiphase Flow’s Volume Fractions Intelligent Measurement by a Compound Method Employing Cesium-137, Photon Attenuation Sensor, and Capacitance-Based Sensor

Combination of a Nondestructive Testing Method with Artificial Neural Network for Determining Thickness of Aluminum Sheets Regardless of Alloy’s Type

Application of the Fourier Transform to Improve the Accuracy of Gamma-Based Volume Percentage Detection System Independent of Scale Thickness

An Insight to the Outage Performance of Multi-Hop Mixed RF/FSO/UWOC System

Intelligent Measuring of the Volume Fraction Considering Temperature Changes and Independent Pressure Variations for a Two-Phase Homogeneous Fluid Using an 8-Electrode Sensor and an ANN

Proposing a Method Based on Artificial Neural Network for Predicting Alignment between the Saudi Nursing Workforce and the Gig Framework

The Role of Biocomposites and Nanocomposites in Eliminating Organic Contaminants from Effluents

An Intelligent Approach to Determine Component Volume Percentages in a Symmetrical Homogeneous Three-Phase Fluid in Scaled Pipe Conditions

Using Ant Colony Optimization as a Method for Selecting Features to Improve the Accuracy of Measuring the Thickness of Scale in an Intelligent Control System

Experimental Analysis to Detect Corona COVID-19 Virus Symptoms in Male Patients through Breath Pattern Using Machine Learning Algorithms

Application of Artificial Intelligence for Determining the Volume Percentages of a Stratified Regime’s Three-Phase Flow, Independent of the Oil Pipeline’s Scale Thickness

Zhumin Cao | Clinical Trials | Best Researcher Award

Published on 12/06/202512/06/2025 by Top Pharmaceutical

Zhumin Cao | Clinical Trials | Best Researcher Award

Prof. Zhumin Cao, The Seventh People’s Hospital of Chongqing, China

Prof. Zhumin Cao is a dedicated clinician and researcher in vascular diseases 🫀, with extensive experience in both basic and clinical research. He has served as a Visiting Scholar at Ajoy University Hospital 🇰🇷 and Carl Gustav Carus University Hospital 🇩🇪. Prof. Cao has led five funded research projects and published 20+ papers, including 10+ SCI articles with a cumulative impact factor of 40+ 📊. His current focus is on early intracavitary treatment of pulmonary embolism, pioneering innovations in patient care. He is also a reviewer for Angiology and Frontiers 📝.

Publication Profile

Scopus

Education

Prof. Zhumin Cao has dedicated his career to clinical and basic research in vascular diseases 🫀. He has served as a Visiting Scholar at Ajoy University Hospital in South Korea 🇰🇷 and University Hospital Carl Gustav Carus in Germany 🇩🇪. His leadership includes two provincial and three departmental-level projects 📊. He actively contributes to the scientific community as a peer reviewer for Angiology and Frontiers 📝. Prof. Cao has authored over 20 research papers, including 10+ SCI-indexed publications, with a combined impact factor of 40+, and a single article IF reaching 11.4 🌟.

Areas of Research

Prof. Zhumin Cao specializes in the field of vascular diseases 🫀, with a primary research focus on the early treatment of pulmonary embolism 🫁—a life-threatening and time-sensitive condition that poses significant challenges in clinical practice ⏱️. His work aims to improve therapeutic strategies and patient outcomes through intracavitary interventions and innovative approaches in vascular care 💉. By bridging clinical application and basic research, Prof. Cao’s studies contribute meaningfully to the development of evidence-based practices in cardiovascular medicine 🌍. His dedication supports advancements in critical care and interventional procedures that save lives every day ❤️.

Research Focus

Prof. Zhumin Cao’s research delves into the role of Interleukin-6 (IL-6) in reshaping the tumor microenvironment 🧫, a key factor in cancer progression and resistance to therapy. His work explores how IL-6-driven changes affect immune cell behavior and tumor dynamics 🧬. By understanding this cytokine’s influence, he aims to enhance the effectiveness of cancer immunotherapy 💉, offering new avenues for targeted treatments. This research bridges oncology and immunology, contributing to breakthroughs in precision medicine 🧠. Prof. Cao’s findings could lead to improved outcomes for patients battling aggressive cancers through innovative immunomodulatory strategies 🎯.

Publication Top Notes

Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Published on 11/06/202511/06/2025 by Top Pharmaceutical

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Dr. Natalia Marina CARDILLO, USDA-ARS-WSU, United States

Dr. Natalia Marina Cardillo is a distinguished veterinary scientist from Argentina with a Ph.D. in Veterinary Sciences, specializing in parasitology and public health 🧫. Currently a Postdoctoral Research Associate at Washington State University 🇺🇸, she focuses on chemotherapeutic strategies for bovine babesiosis. With over two decades of academic and research excellence across UBA, CONICET, INTA, and USDA, she has led groundbreaking projects on zoonoses, antiparasitic drug resistance, and diagnostics. 🧬 Her contributions span teaching, diagnostics, and pharmaceutical clinical trials in veterinary medicine, earning her global recognition and prestigious fellowships.

Publication Profile

Google Scholar

Education

Dr. Natalia Marina Cardillo began her academic path with a Doctor of Veterinary Medicine degree (1997–2004) from the Universidad de Buenos Aires, Argentina, specializing in Public Health 🐕‍🦺🩺. She furthered her expertise by completing a Ph.D. in Veterinary Sciences with a focus on Parasitology and Public Health (2006–2012), earning the prestigious “summa cum laude” distinction for her thesis on Toxocara cati in murine models 🧬🧫. To complement her academic and research proficiency, she pursued a University Teaching Major in Veterinary and Biological Sciences (2014–2016), strengthening her role as an educator and mentor 📚👩‍🏫.

Experience

Dr. Natalia Marina Cardillo has led a distinguished career in parasitology, veterinary microbiology, and public health. Currently a Postdoctoral Research Associate at Washington State University 🐄💊, she focuses on developing novel treatments for bovine babesiosis. Previously, she served as Senior and Principal Scientist at CONICET-INTA 🇦🇷, leading studies on zoonotic parasitic diseases. With over two decades of academic roles at the Universidad de Buenos Aires 👩‍🏫🧫, she also contributed significantly to diagnostics, laboratory accreditation, and veterinary clinical trials. As founder of ALIANZA InVet 🧬🐕, she has pioneered ethical animal research and advanced pharmaceutical testing across Argentina.

Awards

Dr. Natalia Marina Cardillo has received numerous prestigious honors throughout her career. From 2023 to 2025, she was awarded a competitive Postdoctoral Fellowship by the USDA at Washington State University 🇺🇸🔬. In 2018, she won the NAVES entrepreneurship competition by Universidad Austral’s IAE Business School for her CRO-VET project 🏅💼. Her academic excellence was recognized early with a Ph.D. fellowship (2005–2010) in Public Health Veterinary Medicine and a Scientific Research Scholarship (2000–2002) in Parasitology at Universidad de Buenos Aires 🇦🇷📘—highlighting her dedication to veterinary science and innovation.

Research Focus

Dr. Natalia Marina Cardillo’s research is rooted in veterinary parasitology, with a strong emphasis on zoonotic diseases, public health, and epidemiology 🐛🧫🌍. Her work investigates parasites like Toxocara cati, Trichinella spp., and Aelurostrongylus abstrusus, exploring their life cycles, transmission, and pathology in animal hosts and their public health implications 💉📊. She also focuses on developing chemotherapeutic treatments for diseases such as bovine babesiosis, integrating pharmacology, immunology, and molecular diagnostics 🧬💊. Her interdisciplinary research contributes significantly to One Health, bridging human, animal, and environmental health.

Publication Top Notes

Prevalence of Toxocara cati and other parasites in cats’ faeces collected from the open spaces of public institutions: Buenos Aires, Argentina

Trichinella infection in wild animals from endemic regions of Argentina

Experimental Infection with Toxocara cati in BALB/c Mice, Migratory Behaviour and Pathological Changes

Prevalence of canine dirofilariosis in the city of Buenos Aires and its outskirts (Argentina)

Evaluation of the risk of transmission of Trichinella in pork production systems in Argentina

First report of Toxocara cati in the domestic land snail Rumina decollata

Soil contamination with eggs of Toxocara species in public parks of Karaj, Iran

Clinical, haematological, biochemical and economic impacts of Trichinella spiralis infection in pigs

First report of Aelurostrongylus abstrusus in domestic land snail Rumina decollata, in the Autonomous city of Buenos Aires

EXPERIMENTAL INFECTION WITH Toxocara cati IN PIGS: MIGRATORY PATTERN AND PATHOLOGICAL RESPONSE IN EARLY PHASE

Nuevos aportes al conocimiento de Trichinella y trichinellosis

IOANNIS VAMVAKARIS | Precision Medicine | Best Researcher Award

Published on 11/06/202511/06/2025 by Top Pharmaceutical

IOANNIS VAMVAKARIS | Precision Medicine | Best Researcher Award

Dr. IOANNIS VAMVAKARIS, IATROPOLIS, Greece

Dr. Ioannis Vamvakaris is a distinguished Greek pathologist specializing in thoracic pathology. 🫁 He earned his MSc in Thoracic Oncology in 2013 and PhD in 2018 from Athens School of Medicine. 🎓 Since 2019, he has led the Pathology Department at Sotiria General Hospital. 🏥 He’s authored over 200 publications 📚 and co-developed Greece’s first AI software for pathology. 🤖 A reviewer for top journals (Elsevier, MDPI), he actively collaborates on global research in cancer, organoids, proteomics, and microbiome. 🌍 Recognized with the 2024 Best Researcher Award 🏆 and Sigma Xi membership, Dr. Vamvakaris continues to shape medical science with dedication and innovation.

Publication Profile

Google Scholar

Education

Dr. Ioannis Vamvakaris is a highly accomplished pathologist who began his medical journey at Sotiria General Hospital in Athens 🏥. Since 2008, he has served as a consultant in the pathology department, demonstrating unwavering dedication to thoracic pathology 🫁. He earned his MSc in Thoracic Oncology in 2013 and completed his PhD in 2018 from the Athens School of Medicine 🎓. Dr. Vamvakaris also pursued specialized training in Patient-Crisis-Emergency Management at the Berlin School of Economics 🇩🇪. His academic growth and professional excellence highlight his strong commitment to advancing medical knowledge and enhancing patient care globally 🌍.

Awards

Dr. Ioannis Vamvakaris has earned prestigious honors in recognition of his exceptional contributions to pathology and oncology research 🔬. In 2024, he was presented with the Best Researcher Award at the International Research Awards on Oncology and Cancer Research 🧬. That same year, he was inducted as an Associate Member of Sigma Xi 🧠—a globally respected scientific research honor society that recognizes excellence through nomination only. Additionally, he received the Trusted Reviewer Certificate in 2023 📄, reflecting his outstanding commitment to scientific publishing and peer evaluation. These accolades underscore his leadership and integrity in medical science 🌟.o

Research Focus

Dr. Ioannis Vamvakaris is a leading expert in thoracic pathology, with a strong research focus on lung cancer, molecular oncology, and immunopathology 🔬. His studies span non-small cell lung cancer (NSCLC), checkpoint inhibitor-induced sarcoidosis, and PD-1/PD-L1 immune responses 🧬. His collaborative work explores liquid biopsy biomarkers, xenograft models, and AI-assisted diagnostics 🤖. Passionate about translational research, he contributes to genomics, proteomics, fibrosis, and epigenetics in thoracic malignancies. His multidisciplinary efforts bridge clinical pathology and personalized medicine, advancing early diagnosis and targeted therapies 💉. Dr. Vamvakaris’ research enriches global understanding of lung diseases and thoracic oncology 🌍.

Publication Top Notes

Sarcoidosis-like reactions induced by checkpoint inhibitors

Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts

Epithelial–mesenchymal transition in non small-cell lung cancer

Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer

Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection

Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy

Salivary inflammatory markers in tension type headache and migraine: the SalHead cohort study

Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic …

An immunohistochemical evaluation of the proteins W nt1 and glycogen synthase kinase (GSK)‐3β in invasive breast carcinomas

Pulmonary blastoma: a comprehensive overview of a rare entity

Preoperative mutational analysis of circulating tumor cells (CTCs) and plasma-cfDNA provides complementary information for early prediction of relapse: A pilot study in early …

Valory Anne Vailoces | Ophthalmic Pharmacology | Best Researcher Award

Published on 10/06/202510/06/2025 by Top Pharmaceutical

Valory Anne Vailoces | Ophthalmic Pharmacology | Best Researcher Award

Ms. Valory Anne Vailoces, George Washington University School of Medicine & Health Sciences, United States

Ms. Valory Anne Vailoces is a dedicated biomedical scientist and medical student at George Washington University School of Medicine and Health Sciences. She earned her B.S. in Biomedical Sciences from the University of Central Florida in 2021 🎓. Valory conducts impactful ophthalmology research 👁️ under Dr. Michael Tolentino and collaborated with the Miami Itch Center on dermatological studies 🧬. Her pioneering work on rifampicin eye drops for age-related macular degeneration led to a preclinical IND application 💊. She also serves as a senior officer at Hearts for the Homeless International ❤️, combining science with social service.

Publication Profile

Orcid

Education

Valory Anne S. Vailoces earned her B.S. in Biomedical Sciences in 2021 from the University of Central Florida 🧬. She is currently pursuing her medical degree at the George Washington University School of Medicine and Health Sciences 🏥. Alongside her studies, she is actively involved in ophthalmology research 👁️ under the mentorship of Dr. Michael Tolentino. Valory also serves as a senior officer for Hearts for the Homeless International ❤️, a non-profit organization that delivers preventative healthcare services 🩺 to underserved and homeless populations, demonstrating her deep commitment to both science and social impact 🌍.

Professional Memberships

Ms. Valory Anne Vailoces does not currently hold memberships in professional organizations 🤝, her dedication to academic excellence and impactful research in ophthalmology, dermatology, and health management 🧠👁️📊 stands out on its own. Her active involvement in translational research, along with her service to the community through Hearts for the Homeless International ❤️, reflects a strong commitment to both science and humanity 🌍. As she continues to advance in her medical education and research career 🧬, professional affiliations are expected to follow as a natural progression of her growing influence in the field 🚀.

Research Focus

Ms. Valory Anne Vailoces focuses her research on ophthalmology, dermatology, and therapeutic innovation 🧪👁️🧴. Her groundbreaking work includes developing rifampicin eye drops for treating exudative age-related macular degeneration (AMD) 🧬, a major cause of vision loss worldwide 🌍. Additionally, she explores immune-modulating therapeutic nanoparticles for safer clinical applications and leads investigations into aquagenic pruritus, a rare skin condition causing severe itching 💧🧖‍♀️. Through a blend of biomedical science, nanomedicine, and patient-centered studies, Valory contributes to advancing precision treatment modalities with the potential to transform clinical practice 🚀🩺. Her work spans innovative drug delivery and patient quality-of-life research.

Publication Top Notes

Development of Rifampicin Eye Drops for the Treatment of Exudative Age-Related Macular Degeneration

Comprehensive Ocular and Systemic Safety Evaluation of Polysialic Acid-Decorated Immune Modulating Therapeutic Nanoparticles (PolySia-NPs) to Support Entry into First-in-Human Clinical Trials

Aquagenic pruritus: A web‐based survey study exploring itch characteristics, therapeutic options and patient perspectives

Jian Shi | Precision Medicine | Best Researcher Award

Published on 10/06/202510/06/2025 by Top Pharmaceutical

Jian Shi | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Jian Shi, Neurology of UCSF, United States

Assoc. Prof. Dr. Jian Shi is a distinguished neuroscientist at the University of California, San Francisco, with a Ph.D. in Neurobiology from Navy Medical University, China. 🧬 He completed postdoctoral training at the University of Texas Southwestern Medical Center, focusing on neuroscience. His research integrates brain injury, neurodegenerative diseases, and glioblastoma with cutting-edge AI and bioinformatics tools. 🧪🧠 Dr. Shi has authored highly cited publications and received numerous accolades, including the APS Outstanding Paper Award. 🌟 A dedicated mentor and educator, he actively contributes to diversity and public service in neurology and biomedical research.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Jian Shi began his academic journey at the National University of Defense Technology in Hunan Province, China, earning both his B.S. and M.S. degrees in Biomechanics. ⚙️📘 He then pursued his Ph.D. in Neurobiology under the mentorship of Dr. Lu Changlin at the prestigious Navy Medical University in Shanghai. 🧬🏥 Driven by a passion for neuroscience, he completed his postdoctoral training at the University of Texas Southwestern Medical Center under the guidance of Dr. Steven G. Kernie, focusing on advanced neuroscience research. 🧠🔬 His academic foundation bridges biomechanics and cutting-edge neurobiological science.

Awards

Assoc. Prof. Dr. Jian Shi has received numerous accolades recognizing his excellence in research and education. 🇨🇳 He was honored with the prestigious National Award for Scientific Progress, Level 2 in China 🥇🔬 and received the Award for Outstanding Scientists from Navy Medical University, where he also earned the Best Teacher Award for his commitment to academic excellence 👨‍🏫🌟. His groundbreaking work earned him the “Top 50 Most Cited Article Award” from the Journal of Clinical Medicine 📖📈 and the APS Outstanding Paper Award from Acta Pharmacologica Sinica 🧪🏅. He is also recognized as a Trusted Reviewer by the International Journal of Molecular Sciences 🧠✅.

Research Focus

Assoc. Prof. Dr. Jian Shi’s research centers around neurobiology, with a strong emphasis on traumatic brain injury (TBI) 🧠💥, neurodegeneration 🧬, neurogenesis 🌱, and molecular neuroscience. His work explores small molecule therapies, microglial activation, intranasal drug delivery 💊, and microRNA biomarkers, particularly in the context of glioblastoma and stroke. He also investigates brain repair mechanisms, exosomal signaling 📦, and neurotrophin-mimetic compounds. In recent years, his interdisciplinary work has extended to climate impact models 🌍 and machine learning applications 🤖 in brain science, reflecting a comprehensive and innovative research portfolio in translational neuroscience and brain health.

Publication Top Notes

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia

Considering exosomal miR-21 as a biomarker for cancer

The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury

A small molecule p75^NTR ligand protects neurogenesis after traumatic brain injury

MicroRNAs as biomarkers for human glioblastoma: progress and potential

Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers

Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental …

Beneficial effects of minocycline and botulinum toxin–induced constraint physical therapy following experimental traumatic brain injury

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Published on 09/06/202509/06/2025 by Top Pharmaceutical

Konstantinos Tsapakidis | Immunotherapy | Excellence in Research

Assist. Prof. Dr. Konstantinos Tsapakidis, University Hospital Of Larissa, Greece

Assist. Prof. Dr. Konstantinos Tsapakidis 🎓👨‍⚕️ is an esteemed Medical Oncologist at the University of Thessaly, Greece. With a Ph.D. focused on prostate cancer research, he holds European Certification in Medical Oncology 🏅. Since 2018, he has been actively involved in clinical oncology, teaching postgraduate courses on cancer, diet, and immunotherapy 🍽️🧬. Dr. Tsapakidis has authored numerous impactful publications 📚, contributing significantly to cancer diagnostics and treatment. Passionate about education, he trains residents and nurses, advancing oncology knowledge. His expertise includes systemic antineoplastic therapies and immune-oncology 🌟.

Publication Profile

Orcid

Education

Assist. Prof. Dr. Konstantinos Tsapakidis 🎓 is a dedicated Medical Oncologist with an impressive educational background. He earned his Biology degree from Aristotelian University of Thessaloniki 🧬 (1998–2002) and completed his Medicine degree at the University of Thessaly 🏥 (2003–2007). Dr. Tsapakidis achieved his Ph.D. with excellence (2005–2012), researching prostate cancer’s cell-cycle and apoptosis mechanisms 🔬. He specialized in Medical Oncology in 2017 🎯 and obtained the prestigious European Certification in Medical Oncology in 2018 🏅. He also enhanced his expertise through an Immune-Oncology e-learning program at the University of Piraeus in 2017–2018 💻.

Experience

Assist. Prof. Dr. Konstantinos Tsapakidis 💼 has extensive medical oncology experience. Since February 2025, he serves as Assistant Professor at the University of Thessaly 🎓. From 2018 to 2025, he worked as Consultant in Medical Oncology at University Hospital of Larissa 🏥. Previously, he was a University Scholar and Fellow Consultant there (2017–2018) 👨‍⚕️. He completed his residency in Medical Oncology (2014–2017) and earlier trained in Internal Medicine and Hematology at Larissa hospitals 🩺. Between 2008–2009, he was a Scientific Associate in Medical Oncology, laying a strong foundation for his clinical career 🔬.

Research Focus

Assist. Prof. Dr. Konstantinos Tsapakidis’s research focus lies primarily in Medical Oncology with a strong emphasis on cancer diagnosis, treatment, and immunotherapy. 🧬🩺 His work explores various cancer types including lung cancer, breast cancer, sarcomas, and rare cancers, investigating immunotherapy responses, molecular diagnostics, and tumor behavior. 🔬💉 He is particularly involved in studying biomarkers like PD-1/PD-L1, immune cell profiling, and novel therapeutic approaches to improve patient outcomes. 🧪⚕️ His research also covers cancer-associated complications like thrombosis and metastatic disease. Overall, his contributions advance personalized oncology care and innovative cancer treatment strategies.

Publication Top Notes

Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature

The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers

Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients

ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment

Combinatorial analysis of CD4<SUP>+</SUP>Tregs and CD8<SUP>+</SUP>Teff to predict response to ICI in patients with ES-SCLC

Metachronous Single Pulmonary Metastasis of Prostate Cancer: Report of a Rare Case and Literature Review

SYNCHRONOUS DIAGNOSIS OF TESTICULAR AND THYROID CANCER IN A YOUNG MALE

A Proposed Nomogram Model for Recurrence of Non-Muscle Invasive Bladder Carcinoma COMMENT

Metastatic rectal cancer in the ampulla of Vater: A unique case

Radiotherapy and Breast Reconstruction: What Is the Ideal Timing? A Narrative Review

Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden

Daniel Bikle | Pharmacogenomics | Best Researcher Award

Published on 09/06/202509/06/2025 by Top Pharmaceutical

Daniel Bikle | Pharmacogenomics | Best Researcher Award

Dr. Daniel Bikle, University of California San Francisoco, United States

Dr. Daniel Bikle 🧬 is a distinguished physician-scientist specializing in endocrinology and bone metabolism. He earned his A.B. magna cum laude from Harvard 🎓 and M.D. from the University of Pennsylvania 🏥, followed by a Ph.D. in Biochemistry. Currently a Professor of Medicine and Dermatology at the University of California, San Francisco 🌉, he has held key research and clinical roles since the 1970s. Dr. Bikle is renowned for his groundbreaking work on vitamin D and bone health ☀️🦴. He has received numerous awards 🏆 and serves on editorial boards and international scientific committees worldwide 🌍.

Publication Profile

Orcid

Education

Dr. Daniel Bikle’s impressive academic journey began at Harvard University 🎓, where he earned his A.B. magna cum laude in Biochemical Sciences in 1965. He then pursued his medical degree (M.D.) at the University of Pennsylvania School of Medicine 🏥, graduating in 1969. Following medical school, he completed an internship and residency at Peter Bent Brigham Hospital in Boston 🏨 from 1969 to 1971, gaining valuable clinical experience. Dr. Bikle deepened his scientific expertise by earning a Ph.D. in Biochemistry at the University of Pennsylvania in 1974 🔬, laying a strong foundation for his distinguished career in medicine and research.

Awards

Dr. Daniel Bikle has received numerous prestigious honors throughout his career 🏅. Starting with the Harvard Honorary Scholarship 🎓 in 1961 and multiple National Science Foundation Fellowships 🔬 during the 1960s, he earned several prizes at Harvard and the University of Pennsylvania, including the Henderson Memorial Prize 🏆 and Horatio C. Wood Prize in Pharmacology 💊. He was awarded fellowships by NIH and professional societies such as the American College of Physicians and Molecular Medicine 🩺. His later accolades include the Boy Frame Award 🦴 in 2007 and the Louis V Avioli Founders Award in 2016, recognizing his excellence in bone and mineral research.

Research Focus

Dr. Daniel Bikle’s research primarily focuses on vitamin D biology, its metabolism, and its critical role in bone health, skin physiology, and immune function 🦴☀️🧬. His extensive work explores vitamin D receptor actions, calcium signaling, and their impact on processes like wound healing and stem cell behavior 🩹🧪. He investigates vitamin D’s role in diseases such as long COVID and lymphoma, and how it influences cellular differentiation and mineral metabolism 🦠💉. Dr. Bikle also studies the molecular mechanisms of vitamin D in skin and bone, making his research essential for endocrinology, dermatology, and metabolic bone disease fields.

Publication Top Notes

Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows

The Role of the Vitamin D Receptor in the Epidermal Stem Cell Response to Wounding

Vitamin D and Long COVID: Is There a Role in Prevention or Treatment?

Mediator 1 ablation induces enamel-to-hair lineage conversion in mice through enhancer dynamics

Mediator 1 ablation induces enamel-to-hair lineage conversion through enhancer dynamics

Role of vitamin D and calcium signaling in epidermal wound healing

Ligand‐Independent Actions of the Vitamin D Receptor: More Questions Than Answers

Decreased Calcium-Sensing Receptor Expression Controls Calcium Signaling and Cell-To-Cell Adhesion Defects in Aged Skin

Introduction: Special Issue on Vitamin D Dedicated to the Memory of Anthony W Norman

The Free Hormone Hypothesis: When, Why, and How to Measure the Free Hormone Levels to Assess Vitamin D, Thyroid, Sex Hormone, and Cortisol Status

Ablation of Ephrin B2 in Col2 Expressing Cells Delays Fracture Repair

Ohidul Alam | Drug Safety and Risk Management | Best Researcher Award

Published on 09/06/202509/06/2025 by Top Pharmaceutical

Ohidul Alam | Drug Safety and Risk Management | Best Researcher Award

Dr. Ohidul Alam, Jiangsu University, China

Dr. Ohidul Alam is an Environmental Engineer specializing in heavy metals, microplastics, and waste management. He earned his Ph.D. from East China University of Science and Technology (2021) and currently works as a Postdoctoral Fellow at Jiangsu University, China. 🔬 His research focuses on eco-friendly wastewater treatment, hazardous waste recycling, and environmental pollution assessment. With expertise in advanced analytical techniques (ICP-MS, XRF) and life cycle assessment, he has published extensively in top environmental journals. 🧪 Passionate about sustainable development and climate change, Dr. Alam actively contributes to environmental awareness through academic writing and collaborative projects worldwide.

Publication Profile

Google Scholar

Education

Dr. Ohidul Alam has a rich academic background in environmental sciences and engineering 🌱. He earned his Ph.D. in Environmental Engineering from the East China University of Science and Technology, Shanghai 🇨🇳 (2016–2021), preceded by an M.Eng. from the UNEP-Tongji Institute for Sustainable Development, Tongji University (2014–2016) 🧪. Earlier, he completed his M.S. and B.Sc. (Hons.) in Environmental Science from the University of Chittagong, Bangladesh 🇧🇩. His foundational education includes HSC from Government City College and SSC from Shilkhali High School in Cox’s Bazar. 🏫 This strong educational journey laid the groundwork for his impactful environmental research 🌏.

Experience

🧑‍🔬 Dr. Ohidul Alam has built an impressive career in environmental research and sustainability 🌿. Currently, he serves as a Post-doctoral Research Fellow at Jiangsu University, China 🇨🇳. His prior roles include Environmental Officer at SEP-IDF and Consultant at DM WATCH and SETS 🏢. His expertise spans hazardous waste, microplastics, climate change, and wastewater treatment 💧. With experience in academic research, project implementation, statistical analysis, and lab techniques like ICP-MS and XRD 🔬, he also writes on environmental topics for leading dailies 📰. Dr. Alam is fluent in Bangla and English and skilled in SPSS and OriginPro 💻.

Awards

Dr. Ohidul Alam has earned several prestigious awards and scholarships for his outstanding academic and research achievements 🌟. He received the Chinese Scholarship Council (CSC) and Marine Scholarship of China (MSC) in 2014 🇨🇳. In 2015, he was honored with Tongji University President Scholarship (2nd prize) 🥈, followed by the Shanghai Municipal Government Scholarship in 2016 🎓. His paper won first prize at the International Student Conference on Environment and Sustainability in 2017 📄🌍. In 2018, he received the ECUST Comprehensive Scholarship (1st prize) for academic excellence and remarkable research contributions .

Research Focus

Dr. Ohidul Alam’s research primarily focuses on environmental science, with a strong emphasis on waste management, environmental pollution, and sustainability. His work explores diverse aspects such as municipal solid waste management, plastic pollution, heavy metals contamination, and eco-friendly remediation technologies. He contributes significantly to understanding the environmental impacts of plastic bags, healthcare waste management, and green business opportunities in Bangladesh. Additionally, Dr. Alam’s recent interests include adsorption techniques for water purification and life cycle assessments. His interdisciplinary research combines chemistry, engineering, and public health to foster a more sustainable and cleaner environment.

Publication Top Notes

An in-depth review on municipal solid waste management, treatment and disposal in Bangladesh

Characteristics of plastic bags and their potential environmental hazards

Determination of the selected heavy metal and metalloid contents in various types of plastic bags

Heavy metals dispersion during thermal treatment of plastic bags and its recovery

Remediation of heavy metals polluted soil environment: A critical review on biological approaches

A preliminary life cycle assessment on healthcare waste management in Chittagong City, Bangladesh

Application of environmental ethics for sustainable development and conservation of Saint Martin s Island in Bangladesh

A deeper look into the inner factors associated to healthcare waste management in Chittagong–the commercial capital of Bangladesh

An investigation into the green business opportunity for the new entrepreneurs in the municipal wastes recycling sector of Bangladesh

Heavy metals detection and removal from contaminated water: A critical review of adsorption methods A critical review on advances in remediation of toxic heavy metals contaminated solids by chemical processes

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Published on 09/06/202510/06/2025 by Top Pharmaceutical

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Prof. Dr. Takuma Hayashi, National Hospital Organization Kyoto Medical Center, Japan

Prof. Dr. Takuma Hayashi is a renowned Japanese physician-scientist specializing in gynecologic oncology. 🎓 He earned his PhD from the University of Tokyo and trained at MIT’s Whitehead Institute 🧠, contributing to Nobel-linked research. Currently a professor at Shinshu University and Section Head at Kyoto Medical Center 🏥, his groundbreaking work on uterine leiomyosarcoma (LMS) identified LMP2 deficiency as a key biomarker 🔎. Through precision medicine and genomic profiling 🧬, his research has significantly advanced diagnostics and treatment strategies for LMS. With over 30 years of funded research, Dr. Hayashi is globally recognized for revolutionizing women’s cancer care.

Publication Profile

Scopus

Education

Prof. Dr. Takuma Hayashi is a distinguished physician-scientist known for bridging fundamental cancer research with clinical applications. 👨‍⚕️🔬 He is a Professor at Shinshu University Graduate School of Medicine and Section Head at Japan’s National Hospital Organization Kyoto Medical Center. 🎓🏥 Dr. Hayashi earned his PhD from the University of Tokyo and completed postdoctoral training at MIT’s Whitehead Institute under Dr. Rick A. Young. 🎓🇯🇵🇺🇸 He contributed to Nobel Prize-linked AIDS vaccine research with Dr. David Baltimore. With over 30 years of NIH and JSPS funding, his work focuses on molecular research in uterine leiomyosarcoma and ovarian cancer, collaborating with Nobel Laureate Dr. Susumu Tonegawa.

Experience

Prof. Dr. Takuma Hayashi has pioneered precision medicine breakthroughs in uterine leiomyosarcoma (LMS) treatment. 🧬💉 His team used cancer genome panel testing to tailor therapies based on each tumor’s unique genetics. For example, immunotherapy with pembrolizumab led to significant tumor regression, while targeted treatment with pazopanib stabilized disease for months. 🎯💊 Dr. Hayashi’s background from the University of Tokyo and MIT supports his innovative approach. 🚀 His ongoing goals include developing diagnostics, launching clinical trials, expanding global collaboration, and improving patient access to genomic profiling. 🌍💡 His work offers new hope for women facing this aggressive cancer.

Research Focus

Prof. Dr. Takuma Hayashi’s research primarily focuses on molecular oncology and infectious diseases, particularly cancer biomarkers and viral infections. 🧬🔬 His work on uterine leiomyosarcoma involves discovering key diagnostic biomarkers like LMP2 to improve early detection and treatment strategies in aggressive cancers. 🩺🎗️ Additionally, Dr. Hayashi explores infectious diseases such as avian influenza and COVID-19, emphasizing the One Health approach to prevent viral spread between animals and humans. 🦠🌍 His interdisciplinary research bridges cancer biology, immunology, and public health, aiming to develop precision medicine therapies and enhance global disease control efforts.

Publication Top Notes

THE ROLE OF LIVE BIRD MARKETS SHOULD BE EMPHASIZED IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA INFECTIONS

THE IMPORTANCE OF ONE HEALTH IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA/H5N1

Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer

DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER

High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study

POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY